Real-world usage of Chronic Kidney Disease - Mineral Bone Disorder (CKD-MBD) biomarkers in nephrology practices.

Publication Year: 2023

DOI:
10.1093/ckj/sfad290

PMCID:
PMC10784916

PMID:
38223338

Journal Information

Full Title: Clin Kidney J

Abbreviation: Clin Kidney J

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Urology & Nephrology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"CONFLICT OF INTEREST STATEMENT J.B. and M.C. are members of the ckj editorial board. M.F. reports other financial or non-financial interest from Amgen, Abiogen, and Vifor. M.Ga. received payment for lectures/presentation from Baxter, Medtronic, Amicus, BD, Sanofi, Vifor Pharma and support for meetings/travel from Astellas, Sanofi. G.C. received payment for lectures/presentation from Amgen, Vifor, AstraZeneca, Boehringer. G.LM. received payment for lectures/presentation fro Astellas, Vifor, Hansa, Biopharma, Eli-Lily, Travere, GlaxoSmithKline. T.N. received grant support from Amgen and consulting fees from Pharmacosmos. S.F. received consulting fees from Amgen, Myovant, UCB, Amolyt, Radius, Agovos and payment for lectures/presentation from Amgen, UCB, Gedeon Richter. J.B. received consulting fees, payment for lectures/presentation and support for attending meetings and/or travel from AMGEN, Abbvie, Sanofi, CSL-Vifor, Astra-Zeneca, Rubió. M.H. received grants from Diaverum, Resverlogix. M.C.M. received payment for lectures/presentation from Amgen, Vifor Pharma, Abiogen. G.T. reports other financial or non-financial interest from Amgen, Biotest, ABBVIE, Janssen-Cilag, Alexion. The remaining authors have no conflicts of interest to disclose."

Evidence found in paper:

"CONFLICT OF INTEREST STATEMENT: J.B. and M.C. are members of the ckj editorial board. M.F. reports other financial or non-financial interest from Amgen, Abiogen, and Vifor. M.Ga. received payment for lectures/presentation from Baxter, Medtronic, Amicus, BD, Sanofi, Vifor Pharma and support for meetings/travel from Astellas, Sanofi. G.C. received payment for lectures/presentation from Amgen, Vifor, AstraZeneca, Boehringer. G.LM. received payment for lectures/presentation fro Astellas, Vifor, Hansa, Biopharma, Eli-Lily, Travere, GlaxoSmithKline. T.N. received grant support from Amgen and consulting fees from Pharmacosmos. S.F. received consulting fees from Amgen, Myovant, UCB, Amolyt, Radius, Agovos and payment for lectures/presentation from Amgen, UCB, Gedeon Richter. J.B. received consulting fees, payment for lectures/presentation and support for attending meetings and/or travel from AMGEN, Abbvie, Sanofi, CSL-Vifor, Astra-Zeneca, Rubió. M.H. received grants from Diaverum, Resverlogix. M.C.M. received payment for lectures/presentation from Amgen, Vifor Pharma, Abiogen. G.T. reports other financial or non-financial interest from Amgen, Biotest, ABBVIE, Janssen-Cilag, Alexion. The remaining authors have no conflicts of interest to disclose."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025